Edgestream Partners L.P. Sells 2,422 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Edgestream Partners L.P. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,217 shares of the biopharmaceutical company’s stock after selling 2,422 shares during the period. Edgestream Partners L.P.’s holdings in Regeneron Pharmaceuticals were worth $5,483,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REGN. Gilbert & Cook Inc. increased its position in Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after purchasing an additional 146 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 45.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,188 shares of the biopharmaceutical company’s stock worth $1,043,000 after buying an additional 370 shares during the last quarter. Avantax Advisory Services Inc. raised its position in shares of Regeneron Pharmaceuticals by 23.0% during the 4th quarter. Avantax Advisory Services Inc. now owns 1,001 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 187 shares in the last quarter. Financial Advocates Investment Management lifted its holdings in shares of Regeneron Pharmaceuticals by 25.6% in the 4th quarter. Financial Advocates Investment Management now owns 393 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 80 shares during the last quarter. Finally, TrinityPoint Wealth LLC grew its position in Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 12 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Down 0.0 %

Shares of Regeneron Pharmaceuticals stock opened at $1,153.08 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a market cap of $127.05 billion, a price-to-earnings ratio of 34.06, a PEG ratio of 3.97 and a beta of 0.12. The firm’s 50-day moving average is $1,126.24 and its two-hundred day moving average is $1,027.77. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the firm earned $8.79 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Wells Fargo & Company increased their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,109.70.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.